Bcr-TMP, a Novel Nanomolar-Active Compound That Exhibits Both MYB- and Microtubule-Inhibitory Activity

SIMPLE SUMMARY: Recent work has identified the transcription regulator MYB as an interesting therapeutic target for the treatment of certain leukemias and other cancers that are dependent on deregulated MYB activity, such as acute myeloid leukemia (AML) and adenoid cystic carcinoma (ACC). Here we re...

Descripción completa

Detalles Bibliográficos
Autores principales: Yusenko, Maria V., Biyanee, Abhiruchi, Frank, Daria, Köhler, Leonhard H. F., Andersson, Mattias K., Khandanpour, Cyrus, Schobert, Rainer, Stenman, Göran, Biersack, Bernhard, Klempnauer, Karl-Heinz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750090/
https://www.ncbi.nlm.nih.gov/pubmed/35008207
http://dx.doi.org/10.3390/cancers14010043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750090/
https://www.ncbi.nlm.nih.gov/pubmed/35008207
http://dx.doi.org/10.3390/cancers14010043

Ejemplares similares